Education
About Us
Working with TipRanks
Follow Us
Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
ARX Stock Chart & Stats
AU$0.66
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.66
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$207.29M
Enterprise ValueAU$207.73M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,476,200
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth indicates expanding clinical adoption of Aroa's ECM products across wound care and soft-tissue repair. Durable revenue expansion supports scaling commercial operations, improves leverage on fixed costs, and underpins optionality for geographic and indication growth over the next 2-6 months.
Balance Sheet StrengthA high equity ratio and low leverage provide financial resilience, lowering refinancing and solvency risk. This structural strength gives management flexibility to fund commercialization, R&D, or strategic initiatives without immediate pressure from debt maturities, supporting multi-month operational stability.
Strong Gross Margin & Improving EBITDAHealthy gross margins signal competitive product economics and efficient manufacturing. The shift to positive EBITDA demonstrates operational improvement and potential sustainable profitability as revenue scales, implying lasting margin recovery rather than a short-term one-off.
Bears Say
Persistent Net LossesOngoing net losses erode accumulated earnings and limit reinvestment capacity. Even with improving EBITDA, sustained losses constrain long-term profitability, restrict shareholder returns, and may require continued external funding, posing a structural headwind to durable financial health.
Negative Free Cash FlowNegative FCF indicates the business isn't yet self-funding capital needs; reliance on financing can dilute equity or increase obligations. Persistent negative FCF limits the firm's ability to scale commercialization or invest in product development without raising external capital.
Negative Return On EquityA negative ROE shows the company is not converting shareholder capital into profits, signaling inefficiency in capital deployment. This structural weakness can impair investor confidence and raise the cost of future capital, constraining strategic investments over the medium term.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.35 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$207.29M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Currently, no data Available
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Overvalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,476,200 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-2.01%
Trailing 12-Months
Asset Growth
-2.82%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---